Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer’s disease
Olav M. Andersen (Aarhus University)
Matthijs W. J. de Waal (Amsterdam Neuroscience, Amsterdam UMC)
Giulia Monti (Aarhus University)
Niccolo Tesi (TU Delft - Pattern Recognition and Bioinformatics, Amsterdam UMC, Amsterdam Neuroscience)
Anne Mette G. Jensen (Aarhus University)
Christa de Geus (Amsterdam UMC)
Marcel J. T. Reinders (TU Delft - Pattern Recognition and Bioinformatics)
Marc Hulsman (Amsterdam UMC, Amsterdam Neuroscience, TU Delft - Pattern Recognition and Bioinformatics)
Henne Holstege (Amsterdam UMC, Amsterdam Neuroscience, TU Delft - Intelligent Systems)
undefined More Authors
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Background
Protein truncating variants (PTVs) in SORL1 are observed almost exclusively in Alzheimer’s Disease (AD) cases, but the effect of rare SORL1 missense variants is unclear.
Methods
To identify high-priority missense variants (HPVs), we applied ‘domain mapping of disease mutations’ for the 637 unique coding SORL1 variants detected in 18,959 AD-cases and 21,893 non-demented controls.
Results
In this sample, PTVs and HPVs associated with respectively a 35- and 10-fold increased risk of early onset AD and 17- and 6-fold increased risk of overall AD. The median age at onset (AAO) of PTV- and HPV-carriers was 62 and 64 years, and APOE-genotype contributed to AAO-variability. The median AAO of PTV- and HPV-carriers is ~8–10 years earlier than wild-type SORL1 carriers, matched for APOE-genotype. Specific HPVs are highly penetrant and lead to earlier AAOs than PTVs, suggesting possible dominant negative effects.
Conclusion
Our results justify a debate on whether HPV carriers should be considered for clinical counseling.
help_outline